An oral formulation of semaglutide (Rybelsus) is the first oral GLP-1RA approved for treating T2DM [ Table 2 ]
I think the key would be showing that the combination adds real benefit, rather than assuming it will rescue a negative monotherapy result
The sigmoid colon, where colonic intraluminal pressures are greatest, is most commonly affected
They are often compared because both are once-weekly injectable medicines used in type 2 diabetes care, and some formulations are also used for chronic weight management
REP has received consulting fees from Bayer, Corcept Therapeutics, Dexcom, Hanmi Pharmaceutical, Merck, Novo Nordisk, Pfizer, Sanofi, Scohia Pharma and Sun Pharmaceutical Industries, and grants/research support from Hanmi Pharmaceutical, Janssen, Metavention, Novo Nordisk, Poxel and Sanofi